Gavey C J, Szeto M L, Nwokolo C U, Sercombe J, Pounder R E
Academic Department of Medicine, Royal Free Hospital School of Medicine, London, UK.
Aliment Pharmacol Ther. 1989 Feb;3(1):21-8. doi: 10.1111/j.1365-2036.1989.tb00187.x.
Bismuth concentration was measured in plasma, dried leucocytes and urine in nine patients before, during and after treatment with tripotassium dicitrato bismuthate (De-Noltab 2 b.d.) for 6 weeks. During treatment there was an 8.5-fold rise in median plasma bismuth concentration (P less than 0.01), a non-significant doubling of leucocyte bismuth content, and a 349-fold rise in 24-h urinary bismuth excretion (P less than 0.01). The significantly increased urinary bismuth excretion continued for at least 3 months after cessation of treatment with tripotassium dicitrato bismuthate, indicating accumulation of bismuth during treatment with this drug.
